About UCSF Search UCSF UCSF Medical Center

R. Kate (Katie) Kelley, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
kelley_katie

Assistant Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-9888 (appts)
Box 1770, UCSF
San Francisco, CA 94143-1770

View on UCSF Profiles


Education

Harvard College, Boston, MA, B.A., 1993-97, Biochemistry
UCLA, M.D., 1998-2002, Medicine
UCLA, Intern, 2002-05, Medicine
UCLA, Resident, 2005-06, Medicine
UCSF, Fellow, 2006-09, Hematology/Oncology


Professional Experience

  • 2005-2006
    University of California, Los Angeles, Clinical Instructor, Medicine
  • 2010-present
    University of California, San Francisco, Health Sciences Assistant Clinical Professor of Medicine: Step 1
  • 2010-present
    San Francisco Veteran's Administration Medical Center, Staff Physician

Honors & Awards

  • 1993-1997
    Harvard College Scholarship, Harvard College
  • 1993-1997
    Elizabeth Cary Agassiz Merit Award, Harvard College
  • 1997-1998
    Rotary Ambassadorial Scholarship, Costa Rica
  • 2001
    Alpha Omega Alpha, UCLA School of Medicine
  • 2001
    Merck Book Award, UCLA School of Medicine
  • 2001
    Janet M. Glascow Memorial Achievement Citation, American Medical Women's Association
  • 2004, 2006
    Solomon Scholars Resident Research Day Award, UCLA Department of Medicine
  • 2006
    Medical Student Teaching Award, UCLA Department of Medicine
  • 2009
    ASCO Cancer Foundation Merit Award, Gastrointestinal Cancers Symposium
  • 2010
    ASCO Young Investigator Award

Selected Publications

  1. Kelley RK. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J Clin Oncol. 2013 Oct 1; 31(28):3483-6.
    View on PubMed
  2. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7.
    View on PubMed
  3. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7.
    View on PubMed
  4. Kelley RK, Hirose R, Venook AP. Can we cure cholangiocarcinoma with neoadjuvant chemoradiation and liver transplantation? Time for a multicenter trial. Liver Transpl. 2012 May; 18(5):509-13.
    View on PubMed
  5. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9.
    View on PubMed
  6. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):354-62.
    View on PubMed
  7. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011 Nov; 9 Suppl 5:S1-32; quiz S33.
    View on PubMed
  8. Kelley RK, Wang G, Venook AP. Biomarker use in colorectal cancer therapy. J Natl Compr Canc Netw. 2011 Nov; 9(11):1293-302.
    View on PubMed
  9. Kelley RK, Yao F. Salvage liver transplantation for recurrent hepatocellular carcinoma after radiofrequency ablation: a new strategy? J Hepatol. 2012 Jan; 56(1):14-6.
    View on PubMed
  10. Kelley RK, Venook AP. Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling? Clin Colorectal Cancer. 2011 Jun; 10(2):73-80.
    View on PubMed
  11. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91.
    View on PubMed
  12. Kelley RK, Van Bebber SL, Phillips KA, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25.
    View on PubMed
  13. Wang G, Kelley RK. KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic. PLoS Curr. 2010; 2.
    View on PubMed
  14. Kelley RK, Venook AP. Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010 Aug 5; 363(6):596-8.
    View on PubMed
  15. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7.
    View on PubMed
  16. Kelley R, Venook AP. Drug development in advanced colorectal cancer: challenges and opportunities. Curr Oncol Rep. 2009 May; 11(3):175-85.
    View on PubMed
  17. Kelley RK, Venook AP. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008 Dec 20; 26(36):5845-8.
    View on PubMed
  18. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95.
    View on PubMed

Go to UCSF Profiles, powered by CTSI